MUC16 and ovarian cancer: This has limited CA125’s potential as an accurate biomarker for early detection.5–8 Human epididymis secretory protein E4 (HE4/WFDC2), another Food and Drug Administration-approved biomarker for differential diagnosis of ovarian cancer, has similar limitations in detecting early and asymptomatic cancers.9–11